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Abstract 
Background:​ Patients with neovascular age-related macular degeneration (AMD) can avoid 
vision loss via certain therapy. However, methods to predict the progression to neovascular 
age-related macular degeneration (nvAMD) are lacking. 
Purpose:​ To develop and validate a deep learning (DL) algorithm to predict 1-year progression 
of eyes with no, early, or intermediate AMD to nvAMD, using color fundus photographs (CFP). 
Design:​ Development and validation of a DL algorithm. 
Methods:​ ​We trained a DL algorithm to predict 1-year progression to nvAMD, and used 10-fold 
cross-validation to evaluate this approach on two groups of eyes in the ​Age-Related Eye 
Disease Study​ (AREDS): none/early/intermediate AMD, and intermediate AMD (iAMD) only. ​We 
compared the DL algorithm to the manually graded 4-category and 9-step scales in the AREDS 
dataset. 
Main outcome measures:​ Performance of the DL algorithm was evaluated using ​the sensitivity 
at 80% specificity​ for progression to nvAMD. 
Results​: The DL algorithm’s sensitivity for predicting progression to nvAMD from 
none/early/iAMD (78±6%​)​ was higher than manual grades from the 9-step scale (67​±8%) or the 
4-category scale (48±3%​). For predicting progression specifically from iAMD, the DL algorithm’s 
sensitivity (​57±6%)​ was also higher ​compared to the 9-step grades (36​±8%) and the 4-category 
grades ​(​20±0%​). 
Conclusions​: Our DL algorithm performed better in predicting progression to nvAMD than 
manual grades. Future investigations are required to test the application of this DL algorithm in 
a real-world clinical setting. 
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Introduction  
Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss 
among people aged 50 years or older in the industrial world.​1​ Due to a rapid growth in the 
elderly population, the number of individuals visually impaired from AMD is expected to increase 
substantially. It is estimated that 187 million people worldwide currently suffer from AMD, a 
statistic projected to reach 196 million in 2020, and 288 million in 2040.​2 
The diagnosis of AMD is based on the clinical presentation, with drusen being the 
hallmark of early AMD.​3​ Intermediate AMD (iAMD) is characterized by the presence of 
numerous intermediate drusen, at least one large druse, or non-central geographic atrophy 
(GA).​3​ An individual with iAMD is at increased risk of progression to late-stage AMD.​3​ Late (or 
advanced) AMD can be classified into dry or wet forms. Advanced dry AMD is characterized by 
central geographic atrophy (CGA) involving the center of the fovea, while wet (or neovascular) 
AMD (nvAMD), is characterized by the presence of choroidal neovascular membranes that lead 
to severe central vision loss.​4​ Although nvAMD only accounts for approximately 10%–20% of 
the overall incidence of AMD, this subtype is responsible for 90% of cases of severe vision loss 
or legal blindness.​5,6​ In the clinic, nvAMD is routinely managed using anti-vascular endothelial 
growth factor (anti-VEGF) agents.​3​ Thus, identifying patients at greater risk of progressing to 
nvAMD can potentially help clinicians follow these patients closely and initiate treatment in a 
timely manner. 
To study the clinical course, prognosis, and risk factors of AMD and age-related cataract, 
a long term, multicenter, prospective, randomized clinical trial, the Age Related Eye Disease 
Study (AREDS) was performed.​7​ Over the course of the study, several grading scales were 
developed to determine the severity and predict the risk of progression of AMD, such as the 
4-category classification scale (AREDS report number 6),​8​ and the 9-step severity scale 
 
 
 
(AREDS report number 17).​9​ The 4-category scale is a descriptive scale designed to 
standardize grading of color fundus photographs (CFP) for AMD and is widely accepted in 
clinical practice for AMD classification.​3​ The 9-step scale was developed to help determine risk 
of progression to advanced AMD within 5 years. Application of these classification systems in a 
clinic setting, in particular the detailed 9-step scale for disease progression, requires manual 
grading of fundoscopic changes of AMD by trained medical specialists or highly skilled graders, 
a task that is subjective, tedious and time consuming. 
A potential solution to reduce workload and improve consistency of risk stratification is 
deep learning (DL).​10​ DL has been applied to produce highly accurate algorithms that can detect 
eye conditions such as diabetic retinopathy (DR), AMD and glaucoma with accuracy 
comparable to human experts.​11–16​ The use of deep learning based algorithms have been further 
shown to assist eye care providers with DR screening efforts.​17​ ​However, most recent work on 
applying DL to AMD focuses on algorithms for image grading, such as assigning an AMD grade 
for a given CFP​18​ or spectral domain optical coherence tomography (SD-OCT) images,​19​ rather 
than prognosis: predicting progression to nvAMD. 
In this study, we developed and validated a DL algorithm using CFP from the AREDS 
database to identify patients at high risk of progressing to nvAMD within 1-year. We focused on 
two groups: the first group consisted of eyes with either no, early, or iAMD (none/early/iAMD 
group), and the second group consisted only of eyes with iAMD (iAMD group).  
Methods 
Datasets  
The dataset used for the analyses described in this manuscript was obtained from the 
AREDS database found at ​https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=login​ through 
 
 
 
dbGaP accession number [phs000001.v3.p1.c1]. The study protocol was approved by each 
clinical center’s ​institutional review board​.​20 
Grades  
We used grades from two AMD grading scales: the 4-category classification scale and 
the 9-step severity scale. The 9-step scale represents changes seen in early to iAMD, and an 
additional three steps capture late-AMD: CGA (step 10), nvAMD (step 11) and CGA with nvAMD 
(step 12). Since the 4-category scale considers both CGA and nvAMD as advanced AMD, we 
split the 4​th​ category into two subcategories: CGA only, and nvAMD (with or without CGA). 
Distribution of grades across all stereo-pairs are shown in ​Table 1​.  
Grades reversals 
Since CFP from different visits for the same patient were graded independently in the 
AREDS protocol, there were some cases where an eye was graded as having advanced AMD 
in one visit and less than advanced AMD in subsequent visits. However, since such reversals 
are merely an artifact of the graders not having access to prior diagnoses, we excluded the CFP 
where these reversals were observed, as well as subsequent CFP, when developing and 
evaluating our algorithms. 
Data pre-processing 
We used an automated text detection system to discard images that contain text, to 
ensure that the images were completely de-identified. We also discarded images for which we 
were unable to automatically detect the circular boundary (approximately 2% of the images). 
The remaining images were resized to be 587 pixels in each dimension. ​Table 1​ contains the 
statistics of the final dataset used in all experiments. 
 
 
 
Algorithm development 
We developed a DL algorithm that takes stereo pairs of CFP of a single eye as input. We 
trained models in a supervised fashion, feeding a binary label corresponding to whether the eye 
progressed to nvAMD within 1-year after the CFP was captured. The architecture of the model 
was based on ​Inception-v3.​21​ The original ​Inception-v3 architecture​21​ takes a single red, green, 
blue (RGB) image as input. To adapt this architecture to take a stereo pair as input, we used a 
“late fusion” approach: the left and right stereo CFP were each fed into separate Inception-v3 
networks (with shared weights), and the outputs (post-softmax) were averaged. ​Since our 
network had a large number of parameters (22 million), early stopping​22​ was used to terminate 
training before convergence. To speed up training, the network was initialized using parameters 
from a network pre-trained to classify objects in the ImageNet dataset.​23​ The model was trained 
using TensorFlow,​24​ following a procedure similar to that previously described by Krause et al.​12 
Algorithm evaluation 
We used 10-fold cross validation to evaluate our DL algorithm and compare it with the 
4-category and 9-step manual grades’ performance in predicting progression to nvAMD within 
1-year. Specifically, we split the entire AREDS dataset randomly into 10 approximately 
equal-sized partitions that were mutually exclusive with respect to patients. We then used a 
standard 10-fold cross-validation approach: developing a model on 9 of the folds, and 
evaluating the models on the single held-out fold, repeating 10 times such that each of the folds 
was used for evaluation once. In each iteration, within the 9 folds used for development, we 
used one fold for tuning the model (e.g. determining early stopping criteria), and the other 8 for 
training. 
We computed the following metrics: the sensitivity at 80% specificity, receiver operating 
characteristic (ROC) curves, and area under the ROC curve (AUC). The 80% specificity 
 
 
 
operating point was selected using the respective tuning fold, and the specificity and sensitivity 
on the held out “testing” folds was computed. 
Both eyes of each patient were included in the dataset and treated as independent data 
points. However, we observed that eyes that did not progress had, on average, more visits in 
the dataset than eyes that did progress. Hence, treating the ​visits ​as independent data points 
may introduce a bias. To avoid such bias we employed the following strategy: we sampled one 
visit per eye 100 times, computed metrics for each sample and then computed an average to 
produce metrics for each testing fold. Finally, we computed the averages and standard 
deviations of metrics across the 10 folds. 
We computed the metrics on eyes with none/early/iAMD in the test set and also just on 
eyes with iAMD, and evaluated 4-category and 9-step grades on the same 10 folds for purposes 
of comparison, computing all the same metrics as described above (​Figure 1​). 
Results 
Among the none/early/iAMD group, the DL algorithm had a sensitivity of 78±6%, and ​the 
manual grades from the 4-category scale and 9-step scale had sensitivities of 48±3% and 
67±8%, respectively. For the iAMD only group, the DL algorithm had a sensitivity of 57±6%, ​and 
the 4-category grades and 9-step grades had sensitivities of 20±0% and 36±8%, respectively 
(​Table 3 and Figure 2​).  
To further illustrate how the DL model stratifies eyes by their risk of progression, we split 
the data points of each test fold into quartiles by their corresponding DL algorithm prediction and 
computed the actual progression rate in each quartile, and finally averaged these rates across 
the 10 folds. This visualization is shown in ​Figure 3​.​ The eyes predicted by the algorithm to be 
in the highest quartile of progression risk had a 12.4% actual progression rate among 
 
 
 
none/early/iAMD eyes (compared to a baseline rate of 3.7%), and 17.2% progression rate 
among iAMD eyes (baseline of 7.2%). By contrast, the eyes in the lowest quartile had actual 
progression rates below 1%. 
Discussion 
In this study we compared the performance of a DL algorithm with manual grades in 
predicting 1-year progression to nvAMD among two groups: eyes with none, early, or iAMD and 
eyes with iAMD. Our DL algorithm performed better than manual grades in predicting 1-year 
progression.  
Performance of the algorithm 
On the task of predicting progression of None/Early/iAMD eyes to nvAMD within 1-year, 
we observe that our DL algorithm was more sensitive than manual grades from both grading 
scales, and that the 9-step grades outperform the 4-category grades. The latter observation was 
not surprising because the 9-step scale was explicitly developed to predict disease progression 
based on outcomes data, albeit focusing on the 5-year time point.​9​ The superiority of the DL 
algorithm could be due to two factors: the potential inconsistency in manual grading, and the 
ability of the DL algorithm to detect novel features that are not captured in existing grading 
scales. We conducted additional experiments to help dissect these two factors, finding that the 
superior performance is due to both factors, but the former is likely more significant (more 
details in the Appendix). 
On the iAMD group we observe that the DL algorithm was again more sensitive. Note 
that in this group, all the 4-category grades are identical, so the ROC curve is a diagonal line 
corresponding to random performance, and the sensitivity at 80% specificity is 20%. Although 
 
 
 
the DL algorithm outperforms the 9-step grades, we observe that the absolute performance 
numbers of both approaches are lower on the iAMD group than the none/early/iAMD group. 
This is likely because the none/early/iAMD group is a heterogeneous cohort including a number 
of low risk eyes (e.g. no AMD), and the ability to correctly identify these easier cases improves 
the algorithm’s performance. By contrast, the iAMD group is a comparatively more homogenous 
cohort that is more difficult to risk stratify. 
Related work 
Several studies have reported the use of DL algorithms to detect AMD using CFP. 
Burlina et al.​25​ compared the performance of humans and DL algorithm in grading CFP to detect 
AMD. Peng et al.​26​ and Grassmann et al.​18​ developed DL algorithms for automated classification 
of AMD. Recently, Burlina et al.​27​ t​rained a DL algorithm to predict the 9-step grades and also 
the associated known 5-year progression rates to advanced AMD from CFP. By contrast, our 
study aims to directly predict whether an eye will progress to nvAMD within 1-year via binary 
classification. Our approach has the advantage of allowing the DL algorithm to learn any 
features in the CFP that are predictive of progression, instead of restricting it to recapitulate the 
features associated with the 9-step grade. A recent study by Banerjee et al.​28​ used a binary 
classification approach similar to our work, reporting an AUC of 0.68 in predicting fellow-eye 
progression to nvAMD using SD-OCT scans from two visits using a recurrent neural network. Of 
interest, SD-OCT has been reported to be highly sensitive in detecting nvAMD, though it may 
not fully replace CFP or fluorescein angiography (FA) in detecting various lesions in AMD.​29 
Future investigations are required to build a DL algorithm using data captured from multimodal 
imaging wherein CFP, SD-OCT, or FA may complement each other in identifying different 
lesions or types of AMD missed by one or the other imaging technique.  
 
 
 
Limitations 
Our study is not without limitations. AREDS grades were based on assessment of CFP 
alone without the use of FA to validate the ground truth, in particular the nvAMD grades. The 
current model was developed using stereoscopic CFP and may not be applicable to 
two-dimensional images captured in screening programs. In addition, the AREDS cohort lacks 
ethnic diversity and consists mostly of Caucasian participants. Nevertheless, ​our DL algorithm 
could have potential implications in clinical practice for an automated diagnosis of AMD and 
tracking of progression to nvAMD.  
Conclusion 
In conclusion, our study predicted the 1-year progression to nvAMD for two groups of 
eyes in the AREDS dataset, those with either no, early, or iAMD, and those with iAMD. 
Predicting short term progression could help eye care providers identify patients who require a 
closer follow-up in order to detect nvAMD earlier, initiate treatment earlier, and potentially 
achieve better visual acuity outcomes. DL algorithms could also help enrich clinical trials or 
study cohorts with patients who eventually progress, thus aiding future investigations aimed at 
slowing or treating early or iAMD.  
 
  
 
 
 
Tables and Figures  
 
Table 1. Baseline characteristics of dataset 
Patient demographics 
No. of patients 4,628 
No. of eyes 9,221 
No. of stereo pairs 71,772 
Median age at baseline in years (IQR)  69 (65-73) 
Females (%) 40,329 (56%) 
Median No. of visits (IQR) 9 (6-11) 
Distribution of 4-category manual grades across all stereo pairs 
None 22,897 (32%) 
Early 16,547 (23%) 
iAMD  22,297 (31%) 
CGA 1,537 (2%) 
nvAMD 8,494 (12%) 
Distribution of 9-step severity scale manual grades across all stereo pairs 
Step 1 26,471​ (37%) 
Step 2 7,744 (11%) 
Step 3 3,326 (5%) 
Step 4 6,023 (8%) 
Step 5 3,905 (5%) 
Step 6 4,971 (7%) 
Step 7 4,417 (6%) 
Step 8 3,518 (5%) 
Step 9 1,355 (2%) 
 
 
 
CGA (Step 10) 1,537 (2%) 
nvAMD (Step 11) 8,029 (11%) 
CGA+nvAMD (Step 12) 465 (1%) 
Abbreviations: IQR, Interquartile range; iAMD, intermediate age-related macular degeneration; 
CGA, Central geographic atrophy; nvAMD, neovascular age-related macular degeneration;  
 
 
 
 
 
 
 
Table 2. Statistics for 1-year progression to nvAMD in the study dataset 
 none/early/iAMD iAMD 
No. of eyes 8,451 4,468 
No. of visits 61,741 22,297 
No. of visits with an available AMD 
grade at 1-year followup 
41,569 14,731 
No. of visits graded as nvAMD at 
1-year followup 
578 532 
Adjusted* 1-year rate of progression 
to nvAMD per eye 
3.7% 7.2% 
Abbreviations: nvAMD, neovascular age-related macular degeneration; iAMD, intermediate 
age-related macular degeneration. 
This table shows the number of eyes that fell into the none/early/iAMD and iAMD groups at any 
point in the trial, the total number of visits in each group, the subset of those visits that had a 
known outcome (i.e. whether the eye progresses to nvAMD within 1 year), the subset of those 
visits that progress, and a progression rate. *The progression rate is adjusted to avoid biases 
towards eyes with more visits (using the sampling strategy described in the ​Algorithm evaluation 
section in the Methods). 
  
 
 
 
 
Table 3. Comparing performance of the deep-learning algorithm with AMD grades for predicting 
progression to nvAMD at 1-year 
 
None/Early/iAMD iAMD 
AUC* Sensitivity (%) Specificity (%) AUC* Sensitivity (%) Specificity (%) 
4-category 
scale  
0.78±0.2 48±3 80±1 0.50±0.0
0 
 
20±0 80±0 
9-step 
scale 
0.83±0.0
3 
67±8 80±2 0.67±0.0
5 
36±8  80±2 
Deep 
Learning 
0.88±0.0
2 
78±6 80±2 
 
0.77±0.0
4  
57±6 81±4 
Abbreviations: AMD, age-related macular degeneration; nvAMD, neovascular age-related 
macular degeneration; iAMD, intermediate age-related macular degeneration;  
*Results are presented as mean​±std across the 10 cross validation folds. 
 
 
 
 
 
Figure 1. ​(Top) During training, we fed pairs of images and labels into the training algorithm, 
where labels correspond to whether the eye progresses to nvAMD within 1 year after the CFP is 
captured. (Bottom) During evaluation, we either feed the CFP into a trained DL model, or use 
the 4-category or 9-step grade to predict whether the eye will progress to nvAMD within 1 year. 
(fundus photos source:​ ​Häggström, Mikael (2014). "​Medical gallery of Mikael Häggström 2014​". 
WikiJournal of Medicine​ ​1​ (2). ​DOI​:​10.15347/wjm/2014.008​. ​ISSN​ ​2002-4436​. ​Public Domain​) 
 
 
 
 
Figure 2.​ Receiver operating characteristic curve (ROC) of manual grades and deep learning 
(DL) algorithm for predicting progression to neovascular AMD from (left) none/early/intermediate 
AMD and (right) intermediate AMD (iAMD). Error bars indicate standard deviation across the 10 
cross validation folds, and are randomly sampled for visualization purposes. ROC plots for all 
folds are available in the Appendix. 
  
 
 
 
 
 
Figure 3.​ 1-year rate of progression to nvAMD from (left) none/early/intermediate AMD and 
(right) intermediate AMD (iAMD) for the 4 quartiles using our proposed DL algorithm. Error bars 
indicate standard deviation across the 10 cross-validation folds. 
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Appendix 
In this appendix, we explore several hypotheses for why the DL algorithm presented in 
the main text outperforms manual grading along the two grading scales: Is the algorithm picking 
up novel features that the grading scales do not take into account? Is the algorithm using the 
same features as the grading scales, but doing so more consistently than manual grading and 
thus more accurately predicting progression? Or is it simply more accurate because it is not 
constrained to one of a small number of discrete grades? 
To help answer these questions, we explored “two-phase” DL algorithms (​Figure A1​). 
We shall refer to the DL algorithm presented in the main text as “end-to-end” DL algorithm. In 
the two-phase setup, a DL model predicts the AMD grade of the original CFP stereo pair taken 
in the current visit (i.e. the "current" AMD grade), and then uses the ​predicted​ grade to predict 
whether the eye will progress to nvAMD in 1-year. We explored this type of approach for both 
4-category and 9-step grading scales. Furthermore, because a DL algorithm trained to predict 
the current AMD grade outputs a “likelihood” ​distribution ​over the steps in the respective grading 
scales, we also explored a two-phase approach where the predicted distribution over the 
respective grading scale are fed into a logistic regression (LR) model that is trained to predict 
whether the eye will progress to nvAMD within 1-year. We will refer to these two-phase 
algorithms as “two-phase (mode)” that predicts a single grade (i.e., the most likely grade, or 
“mode”), and “two-phase (LR)” that predicts both a distribution over the grading scale as well the 
final progression prediction. 
The performances of two-phase algorithms, end-to-end DL algorithm and manual grades 
from the two grading scales among both none/early/iAMD and iAMD groups are shown in 
Figure A2​ and ​Table A1​, and progression rates are shown for the algorithms that output 
 
 
 
continuous scores in ​Figure A3. ​For the 4-category two-phase models we observed that on 
both none/early/iAMD and iAMD groups, the LR version achieved higher sensitivities than the 
mode version (74±6% and 50±6% vs 54±5% and 31±5%, respectively). Similarly, for the 9-step 
two-phase models, we observed that the LR version achieved higher sensitivities as well 
(76±5% and 46±8% vs 76±6% and 40±7%), but the difference is much smaller compared to 
what we see for the 4-category two-phase models. This suggests that the coarseness of the 
grading scale affects its utility to accurately predict progression; the 9-step scale is fine-grained, 
such that even a single, discrete grade carries enough information to predict progression 
reasonably well. Furthermore, we observe that the two-phase LR algorithms for both the 
4-category and 9-step grading scales achieved similar performance. That is, despite having a 
different granularity, the algorithm-captured likelihood distribution of the two grading scales 
seem to capture similar information regarding progression. 
We also observed that the two-phase (mode) models for both grading scales perform 
better than their corresponding manual grades. For example, the 9-step two-phase (mode) 
model achieved a sensitivity of 40±7% for the iAMD group, while the 9-step manual grades 
achieved a sensitivity of ​36±8%​. This may be due to the model being more consistent than 
human graders, which then enables better progression prediction. 
Finally, we observed that the LR versions of both two-phase models produce results that 
are slightly below that of the end-to-end DL algorithm on both groups, suggesting that an 
end-to-end DL algorithm may be picking up on some features or signals that neither grading 
scale captures. 
 
 
 
 
 
 
 
  
Figure A1​. ​Schematic diagram showing the DL algorithms developed to analyze fundus stereo 
pairs. 
   
 
 
 
 
Table A1. Comparing performance of two-phase models for predicting progression to nvAMD at 1-year  
 
  
None/Early/iAMD 
 
iAMD 
AUC* Sensitivity 
(%) 
Specificity 
(%) 
AUC* Sensitivity 
(%) 
Specificity 
(%) 
4 
category 
Manual 0.78±0.2 48±3 80±1 0.50±0.00 20±0 80±0 
Two-phase 
(mode) 
0.80±0.2 54±5 80±1 0.61±0.03 31±5 80±2 
Two-phase 
(LR) 
0.86±0.2 74±6 80±2 0.74±0.04 50±6 80±3 
9 step Manual 0.83±0.03 67±8 80±2 0.67±0.05 36±8  80±2 
Two-phase 
(mode) 
0.85±0.2 76±6 80±2 0.71±0.02 40±7 80±2 
Two-phase 
(LR) 
0.86±0.2 76±5 80±2 0.74±0.04 46±8 80±3 
DL (end-to-end) 0.88±0.02 78±6 80±2 0.77±0.04  57±6 81±4 
Abbreviations: nvAMD, Neovascular Age-related Macular Degeneration; iAMD, Intermediate 
Age-related Macular Degeneration 
*Results are presented as mean​±std across the 10 cross-validation folds  
 
 
 
 
Figure A2.​ Receiver operating characteristic curve (ROC) analysis comparing two-phase 
algorithms with the end-to-end DL algorithm and manual grades from the two grading scales on 
(left) none/early/intermediate AMD and (right) intermediate AMD. Error bars indicate standard 
deviation across the 10 cross validation folds, and are randomly sampled for visualization 
purposes.  
 
 
 
 
Figure A3.​ Progression to nvAMD from (left) none/early/iAMD and (right) iAMD for quartiles 
using DL scores, and scores from the (LR) versions of the two-phase algorithms for both 
grading scales. 
 
 
 
 
 
 
 
 
 
Figure A4.​ Alternate version of ​Figure 2​ in the main text.  ROC plots showing curves for each 
cross fold rather than standard deviation error bars. 
 
 
